Seemal R. Desai, MD, has been appointed to the US Food & Drug Administration by the United States Department of Health & Human Services. He will be a new member of the FDA Pharmacy Compounding Advisory Committee (PCAC). Nominated by ASDSA/AADA, he will provide advice concerning compounding, medications and federal policy to the FDA. Dr. Desai has previously testified in front of the Committee on the Section 503A bulk substances list. Dr. Desai will begin his term this fall as a full voting FDA member and will be the only in-office practicing physician on the group.